Business Context and Reporting Period
Company: PluriStem Therapeutics Inc. (Note: Input metadata lists "Pluri Inc.", but the filing identifies the registrant as PluriStem Therapeutics Inc.)
Filing Type: Form 8-K (Current Report)
Date: October 6, 2009
Event: Entry into a Material Definitive Agreement regarding a private placement of securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key transaction metrics include:
- Common Stock Issued: 2,702,822 shares
- Stock Price: $1.12 per share
- Warrants Issued: To purchase 1,081,129 shares of Common Stock
- Warrant Exercise Price: $1.60 per share
- Warrant Terms: Exercisable for five years, commencing six months after issuance
- Placement Agent: Roth Capital Partners, LLC
- Placement Fee: 7% of gross proceeds (excluding future warrant exercise consideration)
Operational Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the agreement to raise capital through the sale of equity and warrants. The closing is scheduled to occur no later than October 12, 2009, subject to customary closing conditions. This transaction will increase the company's share count and outstanding warrant obligations.
Guidance, Outlook, and Risks
Management Commentary: The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-151761). A prospectus supplement and base prospectus are being filed with the SEC.
Risks and Contingencies: The transaction is subject to customary closing conditions. The description of the Warrants is a summary and is qualified in its entirety by reference to Exhibit 4.1.
Investor Verification Checklist
- Verify the final closing date and confirmation of funds received (scheduled no later than October 12, 2009).
- Review the full text of the Warrant agreement (Exhibit 4.1) for specific exercise restrictions and dilution impacts.
- Confirm the total gross proceeds after deducting the 7% placement fee.
- Check the updated Form S-3 prospectus supplement for any additional terms or use of proceeds.